FDA
-
-
-
-
-
-
-
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
-
-
-
-
-
-
-
PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule
-
-
-
-
-
-
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen
-
-
-
-
-
-
-
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PEPG
-
-
-
-
-
-
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PEPG
-
-
-
-
-
-
-
Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPG
-
-
-
-
-
-
-
Contact Levi & Korsinsky by August 8, 2025 Deadline to Join Class Action Against PepGen Inc. (PEPG)
-
327,908 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

